AXON:NYE-Axovant Sciences Ltd. (USD)

EQUITY | Aerospace & Defense | New York Stock Exchange

Last Closing

USD 308.23

Change

0.00 (0.00)%

Market Cap

USD 1.28B

Volume

0.30M

Analyst Target

USD 4.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Aerospace & Defense

Symbol Name Price(Change) Market Cap
WWD Woodward Inc

-0.38 (-0.21%)

USD 9.08B
ESLT Elbit Systems Ltd

-1.43 (-0.72%)

USD 8.95B
DRS Leonardo DRS Inc. Common Stock

+0.12 (+0.53%)

USD 5.79B
AVAV AeroVironment Inc

+0.81 (+0.43%)

USD 5.25B
KTOS Kratos Defense & Security Solu..

-0.33 (-1.66%)

USD 2.83B
RKLB Rocket Lab USA Inc.

+0.05 (+1.22%)

USD 2.03B
MRCY Mercury Systems Inc

+0.76 (+2.72%)

USD 1.73B
VSEC VSE Corporation

-4.15 (-5.20%)

USD 1.20B
EH Ehang Holdings Ltd

+0.58 (+3.34%)

USD 1.10B
SWBI Smith & Wesson Brands Inc

-0.11 (-0.67%)

USD 0.77B

ETFs Containing AXON

XAD:CA iShares U.S. Aerospace & .. 4.37 % 0.00 %

-0.18 (-0.30%)

CAD 6.87M
FFTY Innovator IBD® 50 ETF 3.28 % 0.80 %

-0.12 (-0.30%)

USD 0.08B
MMSC First Trust Multi-Manager.. 1.90 % 0.00 %

-0.10 (-0.30%)

USD 0.01B
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.69 % 0.00 %

+0.22 (+-0.30%)

USD 0.04B
EQJS:LSE Invesco NASDAQ Next Gener.. 1.66 % 0.00 %

+3.00 (+-0.30%)

USD 0.04B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.65 % 0.00 %

+0.11 (+-0.30%)

USD 0.05B
EQQJ:SW Invesco NASDAQ Next Gener.. 1.55 % 0.00 %

+0.59 (+-0.30%)

N/A
QWST 1.36 % 0.00 %

N/A

N/A
BBMC JPMorgan BetaBuilders U.S.. 0.64 % 0.00 %

-0.06 (-0.30%)

USD 1.66B
SCHM Schwab U.S. Mid-Cap ETF 0.52 % 0.05 %

N/A

USD 10.83B
JPSC:XETRA JPMorgan BetaBuilders US .. 0.44 % 0.00 %

+0.10 (+-0.30%)

N/A
VB Vanguard Small-Cap Index .. 0.39 % 0.05 %

+0.36 (+-0.30%)

USD 52.45B
CHEP 0.00 % 1.12 %

N/A

N/A
ITA 0.00 % 0.42 %

N/A

N/A
LOUP Innovator Loup Frontier T.. 0.00 % 0.70 %

-0.28 (-0.30%)

USD 0.05B
VBK Vanguard Small-Cap Growth.. 0.00 % 0.07 %

+0.40 (+-0.30%)

USD 16.42B
DFEN Direxion Daily Aerospace .. 0.00 % 1.09 %

-0.42 (-0.30%)

USD 0.16B
BFTR 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

+0.06 (+-0.30%)

USD 0.67B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

+0.19 (+-0.30%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Aerospace & Defense) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.32% 79% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.32% 79% B- 83% B
Trailing 12 Months  
Capital Gain 46.28% 73% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.28% 70% C- 87% B+
Trailing 5 Years  
Capital Gain 25,164.75% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 25,164.75% 100% F 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.95% 76% C+ 78% C+
Dividend Return 17.95% 76% C+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.78% 43% F 44% F
Risk Adjusted Return 44.02% 78% C+ 76% C+
Market Capitalization 1.28B 100% F 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Aerospace & Defense) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 133.43 13% 8%
Price/Book Ratio 14.55 10% 7%
Price / Cash Flow Ratio 122.90 6% 2%
Price/Free Cash Flow Ratio 117.35 3% 2%
Management Effectiveness  
Return on Equity 12.10% 89% 81%
Return on Invested Capital 8.22% 76% 76%
Return on Assets 3.12% 78% 79%
Debt to Equity Ratio 42.00% 16% 46%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.